



OneChain Immunotherapeutics Announces the Appointment of Barbara Krebs-Pohl as New Chair of the Board of Directors

- **Barbara brings over 27 years of experience in the biotechnology and business sectors, having led growth strategies at companies like MorphoSys.**
- **Her appointment strengthens OneChain's vision to continue advancing its pipeline and achieving new milestones in cell therapy development.**
- **Barbara joins at a crucial time, as OneChain prepares for its next phase of growth and expansion.**

Barcelona, 1st June 2025. OneChain Immunotherapeutics (OCI), a clinical-stage biotechnology company focused on the development of CAR T therapies for the treatment of oncologic diseases, has announced the appointment of **Barbara Krebs-Pohl as the new Chair of the Board of Directors.**

Barbara is a highly respected leader in the biotechnology sector with **over 27 years of experience**, particularly in business strategy and alliance development. She has held key positions at renowned companies, including **MorphoSys**, where she served as Chief Business Officer, leading strategies that generated \$2.9 billion in revenue. Her expertise in **strategic partnerships and acquisition integration**, notably with **Constellation Pharmaceuticals Inc.**, played a pivotal role in strengthening MorphoSys's oncology leadership, contributing to its recent **acquisition by Novartis**. Barbara has also served on the board of **HI-Bio**, which was acquired by Biogen in 2024, and is currently the **Managing Director** of the **Foundation for Stem Cell Research and Regenerative Medicine**. Additionally, she is a **Partner and Managing Director** at **Viopas Venture Consulting**, where she advises emerging biotechnology companies on growth and strategic partnerships.

Barbara's appointment comes at a pivotal moment for OneChain, as the company enters its next phase of expansion. **"I am thrilled to be joining OneChain at such an important stage**, with first clinical signals from their frontrunner program in a phase 1 trial," **Barbara said**. "The team's deep expertise in applied science, coupled with a strong commitment to addressing urgent medical needs, makes this an exciting opportunity. **I look forward** to contributing to the company's next steps in corporate development and helping **to further advance their CAR T therapies and allogeneic platform.**"

Laura Rodríguez, Board Member and Principal at Invivo Capital and **Pablo Menendez**, co-founder and CSO of OCI, also expressed their enthusiasm about the appointment, highlighting the significance of this new phase for the company: **"We are delighted to welcome Barbara** as Chair of the Board of Directors of OneChain. **Her**

experience in strategic leadership and business development will be key to guiding its continued success.”

Stefanos Theoharis, CEO of OCI, also shared his excitement about Barbara’s new role, emphasizing the importance of her leadership in steering the company towards its future goals. “As our pipeline continues to evolve and deliver positive data and patient benefits, **Barbara’s experience and proven track record** in company growth, business development and strategic decision-making **will be invaluable**. I am very pleased to welcome Barbara as the new Chair of the BOD and to work closely with her for the continued success of our company”, he added.

About OneChain Immunotherapeutics (OCI)

OCI was **founded** by the Josep Carreras Leukemia Research Institute, ICREA and Dr. Pablo Menéndez **in Barcelona in June 2020**. It is currently supported by a partnership that includes the venture capital firm **Invivo Capital**, the **Center for Technological Development and Innovation** (Ministry of Industry), the venture capital firms **Nara Capital** and **Clave Capital**, and the **Josep Carreras Leukemia Foundation**.

The company, **based at the Barcelona Science Park (PCB)**, is focused on the **development of immunotherapy-based treatments for malignant neoplasms**, based on the research results of the group led by Dr. Pablo Menéndez, ICREA research professor and researcher at the Josep Carreras Leukemia Research Institute.

Currently, OCI is developing **five projects that include** 1) the treatment of **T-cell precursor cortical acute lymphoblastic leukemia (coT-ALL)** with a CAR T already in clinical phase (OC-1). 2) A **dual CAR T** therapy (OC-1d) that could treat up to 80% of patients with **T-type acute lymphoblastic leukemia**. 3) A **CAR T candidate** (OC-2) for the treatment of **B-cell acute lymphoblastic leukemia**. 4) A platform in development of **Vδ1 cells for allogeneic application** (OC-3), which will provide ready-to-use treatments at a lower cost than current autologous CAR T treatments. And, finally, 5) a **dual CAR T therapy** for the treatment of **glioblastoma multiforme**, a highly aggressive brain tumor with fatal prognosis.

Contact

Email | press@scienseed.com (OneChain communication and press office)
Telephone | +34 913766458

 [@onechaintxn](https://www.onechaintx.com/)
<https://www.onechaintx.com/>

 OneChain Immunotherapeutics
<https://www.linkedin.com/company/onechain-immunotherapeutics>